Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Transcatheter Bioprosthetic Aortic Valve Dysfunction: What We Know So Far

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Angiotensin II during Experimentally Simulated Central Hypovolemia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Simplification of Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

OriginalsprogEngelsk
TidsskriftFrontiers in Cardiovascular Medicine
Vol/bind5
Sider (fra-til)45
ISSN2297-055X
DOI
StatusUdgivet - 2018

ID: 56523543